TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26297092

Group type: EXPERIMENTAL
Intervention: Proxy-assessed QOL-AD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subject-assessed QOL-AD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proxy-assessed HUI-3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HUI-3
Number of subjects: 0
Study: 24200407

Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Prolonged conservative treatment
Number of subjects: 150
Study: 21625270

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg once daily for 6 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo once daily for 6 months
Number of subjects: 75
Study: 19076190

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultraviolet B light therapy (UVB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PDL and UVB
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 17768502

Group type: EXPERIMENTAL
Intervention: Reduced indoor air pollution intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fieldworker diagnosis of ALRI
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physician diagnosis of ALRI
Number of subjects: 100
Study: 14963464

Group type: EXPERIMENTAL
Intervention: sildenafil 50 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: apomorphine 2 mg
Number of subjects: 43
Study: 11295624

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 0
Study: 9445291

Group type: EXPERIMENTAL
Intervention: Flow Triggering (FT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pressure Triggering (PT)
Number of subjects: 8
Study: 7976152

Group type: EXPERIMENTAL
Intervention: Overhead radiant heater (ARAGONA Thermal Ceilings TM, CTCX, 1000 W)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Electric blanket (50 W)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard hospital blanket
Number of subjects: 35
Study: 2590271

Group type: EXPERIMENTAL
Intervention: Magnesium-aluminum-antacid (Mucal-Gel)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1207281

Group type: EXPERIMENTAL
Intervention: Acupuncture‐O2‐N2O‐Analgesie (group I)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Neurolept‐Analgesia (group II)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study: 31343761

Group type: EXPERIMENTAL
Intervention: 5 protocolized telephone calls added to usual treatment
Number of subjects: 586

Group type: COMPARATOR
Intervention: Usual treatment only
Number of subjects: 586
Study: 30848033

Group type: EXPERIMENTAL
Intervention: LY+TT223 (3 mg)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: LY+TT223 (2 mg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: LY‐only
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 28404455

Group type: EXPERIMENTAL
Intervention: Posterior-anterior TDCS during iTBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior-posterior TDCS during iTBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TDCS during iTBS
Number of subjects: 0
Study: 25634940

Group type: EXPERIMENTAL
Intervention: Exercise specialist led lifestyle program targeting increased daily walking with individualized daily pedometer step goals for the first 3 months and brisk walking speed, along with substitution of low‐relative to high‐glycemic index foods over the next 3 months.
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 198
Study: 24034079

Group type: EXPERIMENTAL
Intervention: 14-day infusion of NBP followed by NBP capsule
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: 14-day infusion of NBP followed by aspirin
Number of subjects: 573

Group type: COMPARATOR
Intervention: 14-day infusion of ozagrel followed by aspirin
Number of subjects: 573
Study: 21516550

Group type: EXPERIMENTAL
Intervention: Treatment for MA dependence
Number of subjects: 526
Study: 19079997

Group type: EXPERIMENTAL
Intervention: Prophylactic portal vein chemotherapy (PVC) after operation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Radical resection alone (control group)
Number of subjects: 51
Study: 16623676

Group type: EXPERIMENTAL
Intervention: Increased protein nitrogen appearance (0.2 g/kg/day)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Increased Kt/V (0.20 increase)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Increased calcium carbonate use (2 g/day)
Number of subjects: 190
Study: 12767316

Group type: EXPERIMENTAL
Intervention: Flickering light stimulation at 100 mg/dl blood glucose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Flickering light stimulation at 300 mg/dl blood glucose
Number of subjects: 12
Study: 11203940

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide
Number of subjects: 25
Study: 9180311

Group type: EXPERIMENTAL
Intervention: Regent Biogel Reveal gloves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard double-gloves
Number of subjects: 0
Study: 1442596

Group type: EXPERIMENTAL
Intervention: High dosages of diuretics
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Lower dosages of diuretics
Number of subjects: 3600

Group type: EXPERIMENTAL
Intervention: Potassium-sparing antihypertensive regimens
Number of subjects: 3600
Study: 3914582

Group type: EXPERIMENTAL
Intervention: Mg lactate for 16 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for the first 8 weeks, followed by Mg lactate for the next 8 weeks
Number of subjects: 35
Study: 31407644

Group type: EXPERIMENTAL
Intervention: FCU Online with coaching support
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: FCU Online
Number of subjects: 322

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 322
Study: 28967351

Group type: EXPERIMENTAL
Intervention: LSD (100 µg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 27206947

Group type: EXPERIMENTAL
Intervention: Niacin (N)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Ezetimibe/Simvastatin (E/S)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Combination Ezetimibe/Simvastatin/Niacin (E/S/N)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Statins and low-fat diets (systematic review)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Lp(a)-lowering therapies (systematic review)
Number of subjects: 591
Study: 25343656

Group type: EXPERIMENTAL
Intervention: Decisional Balance Feedback (DBF)
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback (PNF)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 724
Study: 22160441

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 446
Study: 20482507

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study: 18929475

Group type: EXPERIMENTAL
Intervention: Camphor-Crataegus berry extract combination (Korodin(®))
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 15977263

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 500
Study: 11849200

Group type: EXPERIMENTAL
Intervention: First antihypertensive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second antihypertensive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third antihypertensive treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender influence on treatment willingness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision-making difficulty influence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Years in full-time education influence
Number of subjects: 0
Study: 11081784

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 mg once daily, increased to 16 mg after 4 weeks)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily, increased to 100 mg after 4 weeks)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study: 8743615

Group type: COMPARATOR
Intervention: Nitrous oxide at 0% concentration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 10% concentration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 20% concentration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 30% concentration
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 40% concentration
Number of subjects: 11
Study: 1527420

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR
Number of subjects: 0
Study: 3936081

Group type: EXPERIMENTAL
Intervention: Citalopram 5 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Citalopram 25 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Citalopram 50 mg
Number of subjects: 26
Study: 30888034

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30355325

Group type: EXPERIMENTAL
Intervention: Real acupuncture group (RAG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo acupuncture group (PAG)
Number of subjects: 0
Study: 27369468

Group type: EXPERIMENTAL
Intervention: Pentax AWS‐S100 videolaryngoscope (AWS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Macintosh (MAC) laryngoscope
Number of subjects: 35
Study: 24909293

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg and 10 mg
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 261
Study: 22750851

Group type: EXPERIMENTAL
Intervention: High Personal Standards condition
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of Personal Standards perfectionism and Evaluative Concerns perfectionism
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-perfectionist condition
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perfectionist conditions (High Personal Standards and Combination of Personal Standards and Evaluative Concerns)
Number of subjects: 100
Study: 20056736

Group type: EXPERIMENTAL
Intervention: Curcumin intervention for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 18685047

Group type: EXPERIMENTAL
Intervention: Pain Checker socks (active treatment)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo socks (control)
Number of subjects: 50
Study: 15798477

Group type: EXPERIMENTAL
Intervention: Paragon CRT lenses
Number of subjects: 18

Group type: COMPARATOR
Intervention: CIBA Vision Focus NIGHT and DAY lenses
Number of subjects: 18
Study: 12844388

Group type: EXPERIMENTAL
Intervention: Low-Copper diet (0.7 mg Cu/d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium-Copper diet (1.6 mg Cu/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-Copper diet (6.0 mg Cu/d)
Number of subjects: 12
Study: 10231502

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor 200 microg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor 400 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8916559

Group type: EXPERIMENTAL
Intervention: BMS180048 25 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: BMS180048 50 mg
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: BMS180048 75 mg
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: BMS180048 (25 mg, 50 mg, 75 mg)
Number of subjects: 209
Study: 29146865

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Lifestyle modification (Control)
Number of subjects: 221
Study: 26947523

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group
Number of subjects: 1575

Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 1575
Study: 25514686

Group type: EXPERIMENTAL
Intervention: Music therapy (group lyric analysis intervention)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Verbal therapy (group talk therapy session)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Wait-list control (eventually received group recreational music therapy intervention)
Number of subjects: 131
Study: 22183938

Group type: EXPERIMENTAL
Intervention: gMS‐Classifier1 (panel of four α‐glucose IgM antibodies)
Number of subjects: 258
Study: 20637969

Group type: EXPERIMENTAL
Intervention: S/N + S4 (sumatriptan 4 mg SC after S/N 85/500 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: S/N + S6 (sumatriptan 6 mg SC after S/N 85/500 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: S100 + S100 (sumatriptan 100 mg PO, 2 tablets administered 2 hours apart)
Number of subjects: 30
Study: 17517804

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 10
Study: 15747123

Group type: EXPERIMENTAL
Intervention: Focal arteriolar narrowing (definition 1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Focal arteriolar narrowing (definition 2)
Number of subjects: 54
Study: 12587622

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 12
Study: 9469360

Group type: EXPERIMENTAL
Intervention: Three cycles of bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Four cycles of bleomycin, etoposide, and cisplatin (BEP)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Serum HCG > 1,000 mIU/mL
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Serum HCG ≤ 1,000 mIU/mL
Number of subjects: 118
Study: 8551469

Group type: COMPARATOR
Intervention: Fetal acoustic stimulation (FAS) using an electrolarynx device for 1-3 seconds before a second version attempt.
Number of subjects: 16
Study: 2229465

Group type: EXPERIMENTAL
Intervention: flurazepam 30 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: flurazepam 15 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: midazolam 15 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study: 713432

Group type: EXPERIMENTAL
Intervention: Intravenous administration of lysine salt of acetylsalicylic acid
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of lysine salt of acetylsalicylic acid
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 7
Study: 31586871

Group type: EXPERIMENTAL
Intervention: Specific exercise programme (balance and jump exercises), performed 4 times per week
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Specific exercise programme (balance and jump exercises), performed at least twice per week
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no specific exercise programme)
Number of subjects: 62
Study: 26142932

Group type: EXPERIMENTAL
Intervention: D3 500,000 IU administered orally as 50,000 IU daily for 10 consecutive days
Number of subjects: 109

Group type: COMPARATOR
Intervention: D2 600,000 IU single mega dose administered orally
Number of subjects: 109
Study: 23874383

Group type: EXPERIMENTAL
Intervention: Supplementary teaching intervention (n = 107 villages)
Number of subjects: 2364

Group type: EXPERIMENTAL
Intervention: Additional kits for girls (n = 54 villages)
Number of subjects: 2364

Group type: COMPARATOR
Intervention: Control group (n = 107 villages)
Number of subjects: 2364
Study: 20725058

Group type: EXPERIMENTAL
Intervention: Both interventions (Soothe/Sleep and Introduction of Solids)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: First intervention only (Soothe/Sleep)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Second intervention only (Introduction of Solids)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 160
Study: 19514576

Group type: EXPERIMENTAL
Intervention: Artificial Bipolar Femoral Head (ABFH)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Anti-Rotation (PFNA)
Number of subjects: 73
Study: 17002571

Group type: EXPERIMENTAL
Intervention: teriparatide 20 or 40 microg/day for a median of 19 months
Number of subjects: 1637

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1637
Study: 12737326

Group type: EXPERIMENTAL
Intervention: Reumacon (CPH82)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 100
Study: 10671902

Group type: COMPARATOR
Intervention: Sparfloxacin 300 mg alone (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose concurrently with sparfloxacin 300 mg (Treatment B)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 2 h after sparfloxacin 300 mg (Treatment C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 4 h after sparfloxacin 300 mg (Treatment D)
Number of subjects: 8
Study: 9348562

Group type: EXPERIMENTAL
Intervention: Oral UFT plus leucovorin
Number of subjects: 0
Study: 8385216

Group type: EXPERIMENTAL
Intervention: beta-blockade condition using i.v. propranolol
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: combined beta‐ and alpha‐blockade condition using both i.v. propranolol and i.v. phentolamine
Number of subjects: 37

Group type: COMPARATOR
Intervention: saline placebo condition
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: alpha‐receptor blockade
Number of subjects: 37
Study: 3535719

Group type: EXPERIMENTAL
Intervention: Netilmicin and piperacillin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Tobramycin and piperacillin
Number of subjects: 118
Study: 29211308

Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 on 5 consecutive days (5-day regimen)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Guadecitabine 90 mg/m2 on 5 consecutive days (5-day regimen)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Guadecitabine 60 mg/m2 on 10 consecutive days (10-day regimen)
Number of subjects: 103
Study: 27255082

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 102
Study: 25137863

Group type: EXPERIMENTAL
Intervention: Intravenous patient controlled analgesia (PCA) with fentanyl
Number of subjects: 34

Group type: COMPARATOR
Intervention: Patient controlled epidural analgesia (PCEA) with Bupivacaine 0.125% plus 2 microgram per ml fentanyl
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups (PCA and PCEA)
Number of subjects: 34
Study: 22091534

Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided aspiration and sclerotherapy with 1% polidocanol (10% of cyst volume)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laparoscopic deroofing
Number of subjects: 40
Study: 20733448

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation (1000 mg vitamin C and 400 IU vitamin E daily)
Number of subjects: 9968

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9968

Group type: EXPERIMENTAL
Intervention: Vitamin C and E supplementation
Number of subjects: 9968
Study: 18026149

Group type: EXPERIMENTAL
Intervention: High-dose melphalan (200 mg/m2) after cyclophosphamide (4 g/m2) for PBPC mobilization
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional chemotherapy (paclitaxel and carboplatin)
Number of subjects: 80
Study: 16221027

Group type: EXPERIMENTAL
Intervention: Couples with infidelity (n = 19)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Men who had participated in affairs
Number of subjects: 134

Group type: COMPARATOR
Intervention: Couples without infidelity (n = 115)
Number of subjects: 134
Study: 12383812

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (Xalatan)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unoprostone 0.15% (Rescula)
Number of subjects: 25
Study: 10673876

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg kg‐1 (n = 21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal saline (control group, n = 21)
Number of subjects: 42
Study: 8849185

Group type: EXPERIMENTAL
Intervention: Project Youth Inform education programme
Number of subjects: 1000
Study: 2181119

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate, 3.1 g every six hours until clinical signs resolved
Number of subjects: 27

Group type: COMPARATOR
Intervention: cefoxitin, 2 g every six hours until clinical signs resolved
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanate
Number of subjects: 27

Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 27
Study: 7008891

Group type: EXPERIMENTAL
Intervention: Propranolol (1000 mg/day)
Number of subjects: 5
Study: 31749128

Group type: COMPARATOR
Intervention: AB-kefir (Bifidobacterium longum, Lactobacillus acidophilus, L. fermentum, L. helveticus, L. paracasei, L. rhamnosus, and Streptococcus thermophiles; total 10 log CFU/sachet) daily for 3 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: AB-kefir
Number of subjects: 56
Study: 31619610

Group type: EXPERIMENTAL
Intervention: Continuous Dewaxed Brown Rice (DBR) ingestion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31287522

Group type: EXPERIMENTAL
Intervention: POEM (n=67)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Pneumatic dilation (n=66)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: POEM
Number of subjects: 133

Group type: COMPARATOR
Intervention: Pneumatic dilation
Number of subjects: 133
Study: 28325472

Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) interstitial brachytherapy with one fraction of 19 Gy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Low-dose-rate (LDR) interstitial brachytherapy with 145 Gy
Number of subjects: 87